Par Pharmaceutical Company Profile

Background

Par Pharmaceutical, established in 1978, is a leading developer, manufacturer, and marketer of high-quality generic and specialty branded pharmaceuticals. The company is committed to providing innovative and cost-effective medications that enhance patient quality of life. Par Pharmaceutical's dedication to quality and value has positioned it among the top five largest generic pharmaceutical companies in the United States.

Key Strategic Focus

Par Pharmaceutical's strategic focus encompasses:

Core Objectives: To develop and deliver safe, innovative, and cost-effective pharmaceutical products that improve patient outcomes.

Areas of Specialization: The company specializes in complex generic drugs, including controlled substances, injectables, and modified-release oral solids.

Key Technologies Utilized: Par Pharmaceutical employs advanced manufacturing technologies and maintains a robust research and development pipeline to support its product offerings.

Primary Markets Targeted: The company primarily serves the U.S. market, focusing on providing affordable access to essential medications.

Financials and Funding

In 2015, Par Pharmaceutical was acquired by Endo International plc, a global specialty pharmaceutical company. This acquisition expanded Endo's generics business, positioning it among the top five industry leaders.

Pipeline Development

Par Pharmaceutical has a promising product pipeline, with over 200 Abbreviated New Drug Applications (ANDAs) filed with the U.S. Food and Drug Administration (FDA) as of December 31, 2014. Approximately 33% of these filings are potential first-to-file or first-to-market opportunities, and 75% of the overall development portfolio consists of Paragraph IV and first-to-file programs, which could provide periods of market exclusivity upon approval.

Technological Platform and Innovation

Par Pharmaceutical distinguishes itself through:

Proprietary Technologies: The company utilizes advanced manufacturing processes and technologies to produce complex generic drugs.

Significant Scientific Methods: Par Pharmaceutical employs rigorous research and development methodologies to ensure the efficacy and safety of its products.

Leadership Team

The leadership team at Par Pharmaceutical includes:

Paul V. Campanelli: Chief Executive Officer (CEO)

Terrance J. Coughlin: Chief Operating Officer (COO)

Thomas J. Haughey: General Counsel and Chief Administrative Officer

These leaders bring extensive experience in the pharmaceutical industry, guiding Par Pharmaceutical's strategic direction and operations.

Leadership Changes

In 2015, Par Pharmaceutical underwent significant leadership changes following its acquisition by Endo International plc. The integration of Par's operations into Endo's generics business led to the appointment of new leadership to drive the combined entity's growth and strategic initiatives.

Competitor Profile

Market Insights and Dynamics

The generic pharmaceutical market is characterized by intense competition, with numerous companies vying for market share. Key competitors include Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and others. The market is influenced by factors such as regulatory changes, pricing pressures, and the need for innovation in drug development.

Competitor Analysis

Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva offers a broad portfolio of generic drugs across various therapeutic areas.

Aurobindo Pharma Ltd.: An Indian multinational pharmaceutical company, Aurobindo specializes in generic pharmaceuticals and active pharmaceutical ingredients.

Amneal Pharmaceuticals LLC: A U.S.-based company focusing on the development and manufacturing of generic and specialty pharmaceuticals.

Strategic Collaborations and Partnerships

Par Pharmaceutical's acquisition by Endo International plc in 2015 was a strategic move to enhance its generics business and expand its product portfolio.

Operational Insights

Par Pharmaceutical's integration into Endo International plc has strengthened its market position, leveraging Endo's resources and expertise to enhance operational efficiency and expand its product offerings.

Strategic Opportunities and Future Directions

Par Pharmaceutical continues to focus on expanding its product pipeline, particularly in complex generic drugs, to meet the evolving needs of the healthcare market. The company's strategic direction includes leveraging Endo International plc's global presence and resources to drive growth and innovation.